Inventiva S.A. (6IVA)
XFRA 
Summary
6IVA Chart
Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Inventiva (IVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Inventiva's Speculative Upside Through MASH Is Promising
Inventiva is now essentially a lanifibranor bet. Their prospects hinge on the upcoming Phase 3 NATiV3 readout, which we should get by Q4 2026. In my view, lanifibranor seems relatively differentiated after its Phase 2b results. Management is narrowing its focus solely on this MASH asset. IVA's balance sheet has sufficient financing to reach that readout. But please bear in mind that it's a binary outcome.
Inventiva S.A. (IVA) Q4 2025 Earnings Call Transcript
Inventiva S.A. (IVA) Q4 2025 Earnings Call Transcript
Inventiva S.A. (6IVA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Inventiva S.A. ever had a stock split?
Inventiva S.A. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Andrew Obenshain CEO | XFRA Exchange | US46124U1079 ISIN |
| FR Country | 69 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Inventiva S.A. is a trailblazer in the biopharmaceutical field, primarily engaged in discovering and developing oral small molecule therapies. Established in 2011, and operating from its headquarters in Daix, France, the company has positioned itself at the forefront of tackling complex diseases, with an emphasis on non-alcoholic steatohepatitis (NASH) and a variety of other significant diseases. Venturing beyond the traditional boundaries of medicine, Inventiva is committed to innovating solutions that have the potential to reshape treatments and improve patient outcomes significantly.
Products and Services
- Lanifibranor
Inventiva's flagship product, Lanifibranor, is an oral small molecule therapy currently undergoing a Phase III clinical trial aimed at treating non-alcoholic steatohepatitis (NASH), a liver disease with limited current treatment options. This therapeutic candidate stands out for its ability to address a critical unmet need in the healthcare sector, offering hope to patients suffering from this progressively worsening condition.
- Odiparcil
Another innovative product in Inventiva’s portfolio is Odiparcil, a therapy that has completed Phase IIa clinical trials and is designed to treat mucopolysaccharidoses type VI disease. This rare and serious condition affects the body's ability to break down large molecules, leading to severe symptoms that impact the quality of life. Odiparcil represents Inventiva’s commitment to addressing rare diseases with high unmet medical needs, showcasing the company's dedication to extending its research and development capabilities beyond its primary focus areas.
Beyond these leading product candidates, Inventiva continues to expand its horizon with a pipeline that encompasses earlier-stage programs targeting oncology and several other diseases. This approach exemplifies the company's strategic vision towards diversification and innovation, aiming to leverage its expertise in drug development to contribute significantly across a broad spectrum of healthcare challenges.
